Research programme: interleukin 23 antagonists - Archemix/Elan
Latest Information Update: 02 Mar 2011
At a glance
- Originator Archemix Corporation; Elan Corporation
- Class Oligonucleotides
- Mechanism of Action Interleukin 23 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammatory bowel diseases; Multiple sclerosis; Psoriasis; Rheumatoid arthritis
Most Recent Events
- 27 Apr 2007 This programme is still in active development
- 17 Aug 2005 This programme is still in active development - (BIO-2005)
- 28 Jul 2004 Preclinical trials in Multiple sclerosis in USA (unspecified route)